SkinHealth Systems Inc. filings document the regulatory record for a Nasdaq-listed medical aesthetics company formerly known as The Beauty Health Company. The filings identify its Class A common stock, operating and financial results, non-GAAP reconciliations, and material-event disclosures tied to quarterly and annual reporting.
Its SEC record also includes proxy materials for annual stockholder voting, board and committee governance, director appointments, officer departures, compensatory arrangements, capital-structure disclosures and shareholder voting matters. These filings provide the formal disclosure framework for the company behind Hydrafacial, SkinStylus and related professional skin-health offerings.
Form 4 Overview – The Beauty Health Company (SKIN)
Director Desiree Gruber filed a Form 4 reporting the award of 73,051 Class A common-stock RSUs on 16 June 2025. The award was coded “A” (acquired) and represents equity compensation rather than an open-market purchase. After this grant, Gruber’s total beneficial ownership rises to 192,565 shares, all held directly.
Vesting Terms
- The RSUs vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the 2026 annual meeting of shareholders.
- Continuous board service is required through the vesting date.
Key Takeaways for Investors
- The filing signals continued board-level alignment with shareholders, although the grant is part of the regular director compensation program rather than a discretionary purchase.
- No derivative securities transactions were reported, and no shares were disposed of.
- The transaction does not alter the company’s cash position or share count today, but it will have a modest dilutive effect upon vesting.
Form 4 filing for The Beauty Health Company (SKIN) discloses that director Michelle C. Kerrick was granted 73,051 restricted stock units (RSUs) on 06/16/2025 (Transaction Code A).
• The RSUs vest on the earlier of the one-year anniversary of the grant or the date of the company’s 2026 annual shareholders’ meeting, subject to her continued board service.
• After the grant, Kerrick’s total beneficial ownership increases to 189,813 Class A shares, held directly.
• No derivative securities were involved and no shares were sold.
The filing represents routine director equity compensation and does not indicate any open-market buying or selling activity.
Beauty Health Company (ticker: SKIN) filed a Form 4 disclosing an insider equity grant. Director Brian Christopher Miller received 73,051 Class A common-stock RSUs on 16 June 2025. The award is classified as an acquisition (Code A) and is part of routine director compensation.
The RSUs will vest on the earlier of the one-year anniversary of the grant or the 2026 annual shareholder meeting, subject to Miller’s continued board service. Following the grant, Miller’s beneficial ownership increased to 243,035 shares, held directly. No derivative securities or sales were reported, and no 10b5-1 trading plan was indicated.
Beauty Health Company (SKIN) – Form 4 insider filing
Director Doug K. Schillinger reported the grant of 73,051 restricted stock units (RSUs) on 16 Jun 2025. The award is coded "A" (acquisition) and is part of the company’s director compensation program rather than an open-market purchase. Vesting occurs on the earlier of (i) the one-year anniversary of the grant or (ii) the 2026 annual shareholders’ meeting, subject to the director’s continued board service.
Following this grant, Schillinger’s total beneficial ownership increased to 216,035 Class A common shares, all held directly. No derivative securities were reported.
The filing signals continued equity-based alignment between the board and shareholders but does not, by itself, alter Beauty Health’s financial outlook or capital structure.